Top-Rated StocksTop-RatedNASDAQ:MRUS Merus (MRUS) Stock Price, News & Analysis → Buy Friday, Sell Monday, No Exceptions (From DTI) (Ad) Free MRUS Stock Alerts $44.84 +0.09 (+0.20%) (As of 03:29 PM ET) Add Compare Share Share Today's Range$43.87▼$45.2550-Day Range$31.86▼$51.8252-Week Range$17.15▼$52.03Volume444,683 shsAverage Volume586,069 shsMarket Capitalization$2.60 billionP/E RatioN/ADividend YieldN/APrice Target$52.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Merus alerts: Email Address Merus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside19.4% Upside$53.55 Price TargetShort InterestHealthy7.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.32) to ($3.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.96 out of 5 starsMedical Sector831st out of 938 stocksPharmaceutical Preparations Industry383rd out of 433 stocks 3.5 Analyst's Opinion Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.55, Merus has a forecasted upside of 19.4% from its current price of $44.84.Amount of Analyst CoverageMerus has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.08% of the outstanding shares of Merus have been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Merus has recently decreased by 8.07%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MRUS. Previous Next 2.6 News and Social Media Coverage News SentimentMerus has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Merus this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for MRUS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Merus to their MarketBeat watchlist in the last 30 days. This is a decrease of -46% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Merus is held by insiders.Percentage Held by Institutions96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($3.32) to ($3.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -14.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -14.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 7.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Merus Stock (NASDAQ:MRUS)Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Read More MRUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRUS Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Given Consensus Recommendation of "Buy" by BrokeragesMarch 11, 2024 | finance.yahoo.comMRUS Dec 2024 50.000 callMarch 28, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 10, 2024 | finance.yahoo.comMRUS Jan 2025 50.000 putMarch 9, 2024 | finance.yahoo.comMRUS Apr 2024 35.000 putMarch 9, 2024 | finance.yahoo.comMRUS Apr 2024 40.000 callMarch 6, 2024 | marketwatch.comGilead, Merus to Collaborate on Trispecific Antibody ResearchMarch 6, 2024 | msn.comGilead to invest in Merus as part of a research dealMarch 28, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 6, 2024 | finance.yahoo.comMerus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expressionMarch 6, 2024 | finance.yahoo.comGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersMarch 5, 2024 | finance.yahoo.comMerus Full Year 2023 Earnings: Misses ExpectationsMarch 4, 2024 | markets.businessinsider.comStrong Buy Rating for Merus’s Peto: Anticipating High Market Potential and Synergistic Treatment EfficacyMarch 2, 2024 | finance.yahoo.comEarnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported And Analysts Are Trimming Their ForecastsMarch 1, 2024 | seekingalpha.comMerus: Positive Zenocutuzumab Data In 2024 Could Provide BLA AdvancementMarch 1, 2024 | markets.businessinsider.comMerus’s Upgraded Outlook: Buy Rating and Price Target Boost Amid Promising Drug Trials and Financial StabilityFebruary 29, 2024 | finance.yahoo.comMRUS Apr 2024 40.000 putFebruary 29, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Merus (MRUS)February 29, 2024 | markets.businessinsider.comBuy Rating Affirmed on Merus’s Stock Amid Strong Clinical Developments and Market PotentialFebruary 28, 2024 | finanznachrichten.deMerus N.V.: Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business UpdateFebruary 28, 2024 | globenewswire.comMerus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business UpdateFebruary 16, 2024 | finance.yahoo.comMRUS Mar 2024 40.000 callFebruary 16, 2024 | finance.yahoo.comMRUS Sep 2024 55.000 callFebruary 8, 2024 | markets.businessinsider.comBuy Rating on Merus Stock Amid Anticipated Phase 3 Trial and Promising Treatment Efficacy for HNSCCFebruary 5, 2024 | finance.yahoo.comMerus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth PlansJanuary 31, 2024 | finance.yahoo.comMerus to Participate in Upcoming Investor ConferencesJanuary 23, 2024 | seekingalpha.comMerus Stock: Rally Seems OverdoneSee More Headlines Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRUS CUSIPN/A CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees172Year FoundedN/APrice Target and Rating Average Stock Price Target$52.00 High Stock Price Target$65.00 Low Stock Price Target$35.00 Potential Upside/Downside+16.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,940,000.00 Net Margins-352.56% Pretax Margin-345.30% Return on Equity-50.61% Return on Assets-37.56% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio5.34 Sales & Book Value Annual Sales$43.95 million Price / Sales58.93 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book7.25Miscellaneous Outstanding Shares57,880,000Free Float55,389,000Market Cap$2.59 billion OptionableOptionable Beta1.12 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Sven Ante Lundberg M.D. (Age 61)CEO, President & Executive Director Comp: $953.06kMr. Gregory D. Perry (Age 64)Chief Financial Officer Comp: $63.76kMr. Peter B. Silverman J.D. (Age 46)EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal Comp: $601.19kDr. Hui Liu Ph.D. (Age 57)Chief Business Officer, Executive VP & Head of Merus U.S. Comp: $597.7kDr. Andrew Joe M.D. (Age 57)Chief Medical Officer & Senior VP Comp: $692.74kDr. Hennie HoogenboomCo-Founder and Scientific AdvisorHarry ShumanChief Accounting OfficerMr. Cornelis Adriaan de Kruif Ph.D. (Age 59)CTO & Executive VP Comp: $352.93kDr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Senior VPKathleen FarrenIR & Corporate Communications OfficerMore ExecutivesKey CompetitorsEvotecNASDAQ:EVOGemini TherapeuticsNASDAQ:GMTXSummit TherapeuticsNASDAQ:SMMTCorcept TherapeuticsNASDAQ:CORTMorphoSysNASDAQ:MORView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 27,093 shares on 3/11/2024Ownership: 0.263%Wellington Management Group LLPSold 725,844 shares on 3/5/2024Ownership: 3.472%Goldman Sachs Group Inc.Bought 180,967 shares on 3/1/2024Ownership: 0.670%Sierra Summit Advisors LLCBought 8,049 shares on 2/22/2024Ownership: 0.014%Legal & General Group PlcSold 1,848 shares on 2/15/2024Ownership: 0.060%View All Insider TransactionsView All Institutional Transactions MRUS Stock Analysis - Frequently Asked Questions Should I buy or sell Merus stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRUS shares. View MRUS analyst ratings or view top-rated stocks. What is Merus' stock price target for 2024? 12 analysts have issued 12 month target prices for Merus' stock. Their MRUS share price targets range from $35.00 to $69.00. On average, they expect the company's share price to reach $53.55 in the next year. This suggests a possible upside of 19.4% from the stock's current price. View analysts price targets for MRUS or view top-rated stocks among Wall Street analysts. How have MRUS shares performed in 2024? Merus' stock was trading at $27.50 at the start of the year. Since then, MRUS shares have increased by 63.1% and is now trading at $44.84. View the best growth stocks for 2024 here. When is Merus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our MRUS earnings forecast. How were Merus' earnings last quarter? Merus (NASDAQ:MRUS) announced its earnings results on Wednesday, February, 28th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.71) by $0.38. The biotechnology company had revenue of $8.94 million for the quarter, compared to analyst estimates of $10.43 million. Merus had a negative trailing twelve-month return on equity of 50.61% and a negative net margin of 352.56%. What ETFs hold Merus' stock? ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco Nasdaq Future Gen 200 ETF (QQQS). What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC). When did Merus IPO? Merus (MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. Who are Merus' major shareholders? Merus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Commodore Capital LP (8.22%), Federated Hermes Inc. (6.30%), RTW Investments LP (4.11%), Wellington Management Group LLP (3.47%), Franklin Resources Inc. (3.26%) and Balyasny Asset Management L.P. (2.14%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg. View institutional ownership trends. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRUS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry ResearchSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.